DIABETESpredict™ is a laboratory test which provides a high-sensitivity and –specificity evaluation of the genetic predisposition to develop type 2 diabetes (T2D). Furthermore, it offers personalized recommendations based on the patient’s genetic profile.
The test was developed in collaboration with scientists and endocrinologists at The Massachusetts General Hospital (Boston, MA) and The Broad Institute of MIT & Harvard (Cambridge, MA).
diabegen™ analyzes the genes associated with the development of type 2 diabetes. Some genes affect cellular processes, such as reduced beta-cell production or decreased beta-cell function, which impact insulin production. Other genes are associated with increased insulin resistance, resulting from complex processes such as obesity, hypothalamic dysregulation, dyslipidemia and other conditions.
Patia has developed MATERgen, a high-throughput genotyping test that analyzes genetic variants associated with the development of gestational diabetes (GDM).
- MATERgen has been clinically validated with 4 large multiethnic paneuropean patient cohorts – 4,000 GDM patients and controls.
- High sensitivity and specificity were shown AUC=0.75.